The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site ...

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in 2026 on Tuesday, banking on strong demand for cancer drugs and new launches ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...

There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

AstraZeneca CEO Pascal Soriot says the pharmaceutical giant is still not ready to restart its paused U.K. investments, ...

As the oral weight-loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its ...

AstraZeneca stock rose 230p (1.64 per cent) to 14,118 per share within an hour of the London stockmarket opening this morning ...

AstraZeneca (LON:AZN) projected continued revenue and earnings growth in 2026 on Tuesday, while its results for the fourth quarter came in line with expectations.